Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
 World Congress - EconoTimes)
SAN DIEGO, April 23, 2018 -- Samumed, LLC, a leader in Wnt research and development, today announced it will present its most recent clinical and preclinical data on the company’s investigational Wnt pathway inhibitors for the treatment of osteoarthritis (SM04690) and tendinopathy (SM04755) at the 2018 Osteoarthritis Research Society International World Congress, to be held April 26-29, 2018 in Liverpool, U.K.
“We are honored to present our work on the first potential disease modifying treatment in osteoarthritis and our first-in-class topical tendinopathy treatment at the OARSI congress. Our encouraging findings continue to drive our innovative research in Wnt pathway modulation for potential therapeutic options currently lacking in the clinical space,” said Dr. Yusuf Yazici, Samumed’s Chief Medical Officer.
Oral Presentation Details:
| Abstract Title | Date/Time | Session Title |
| Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway – Oral Presentation #27 | Friday, April 27 10:45-12:00pm BST | Plenary Session 4 – Non-Cartilaginous Soft Tissues in OA: Tendons, Ligaments and Synovium |
Poster Presentation Details:
Further details can be found on the OARSI website at https://2018.oarsi.org/. A copy of the presentation materials can be accessed by visiting the Publications section of the Samumed website after the presentations conclude.
In addition, Samumed will be holding a scientific symposium at 12:15pm BST on Saturday, April 28 entitled, “Advancing Disease Modification in Knee Osteoarthritis: Clinical Implications of Wnt Pathway Inhibition.” This symposium will feature highly esteemed faculty: Dr. Timothy McAlindon, Dr. Rik Lories, Dr. Nancy E. Lane, and Dr. Yusuf Yazici.
About Osteoarthritis Research Society International
The Osteoarthritis Research Society International (OARSI) is the leading medical society for advancing the understanding, early detection, treatment and prevention of osteoarthritis (OA) through its exclusive dedication to research. OARSI’s passion and area of focus is on OA, a debilitating disease affecting more than 600 million people around the world. With more than 30 years of experience serving the OA community, OARSI provides the necessary framework, expert resources and support for its international constituents to address the challenges of OA so that the knowledge gained can ultimately be used to help improve patient care and patient outcomes.
About SM04690
SM04690 is a small molecule inhibitor of the Wnt pathway administered as an intra-articular injection, and is being developed as a potential disease modifying drug for osteoarthritis (DMOAD). Preclinical data suggested SM04690 has a dual mechanism of action with three specific effects on joint health – generating new articular cartilage, slowing down cartilage degradation, and reducing inflammation in the joint. Additional information on Samumed’s SM04690 osteoarthritis program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=20
About SM04755
SM04755 is a small-molecule Wnt pathway inhibitor and is being developed as a potential topical therapeutic for tendinopathy. Preclinical data on SM04755 have been previously shown to inhibit inflammation, reduce fibrosis, and increase tenocyte differentiation (tendon repair). Additional information on Samumed’s SM04755 tendinopathy program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=13
About Samumed
Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Samumed’s clinical pipeline can be found here: https://www.samumed.com/pipeline/default.aspx
Corporate Contact:
Erich Horsley
Samumed, LLC
[email protected]
858-365-0200
Investor Contact:
Ashley Robinson
LifeSci Advisors
[email protected]
617-535-7742
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
[email protected]
646-627-8384
